Company intelligence / Profile preview

Oxurion

Ownership: Public · OXUR
Employees: ~20
Development stage: Phase 2

Overview

Oxurion has developed a portfolio of disease-modifying therapies for retinal disorders. Its most advanced programs have included THR-317, THR-149, and THR-687 targeting DME and diabetic retinopathy. The company also owns Jetrea® (ocriplasmin), approved for vitreomacular adhesion/traction. Current focus includes preclinical work using a CRISPR-based platform to identify new targets in geographic atrophy.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeMonoclonal antibodyRecombinant proteinCRISPR-based therapyPeptide
Industry: Biotech

Drug pipeline

7 assets

ocriplasmin

6 more assets in the full pipeline.

Request access →

Partnerships

Prevent Blindness US partnership for awareness campaigns related to diabetic eye disease

Financials

Market cap: $723.4M
Total revenue: $1.5B

Beyond the preview

Go deeper on Oxurion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxurion.

Explore the full profile